FREE Account Opening + No Clearing Fees
Loading...

Gland Pharma IPO vs Route Mobile IPO

Comparision between Gland Pharma IPO and Route Mobile IPO.

IPO Details

Gland Pharma IPO is a Mainline Book Built Issue IPO proposed to list at BSE, NSE while Route Mobile IPO is a Mainline Book Built Issue proposed to list at BSE, NSE.

Issue Size and Price

The total issue size of Gland Pharma IPO is up to ₹6,479.55 Cr whereas the issue size of the Route Mobile IPO is up to ₹600.00 Cr. The final issue price of Gland Pharma IPO is ₹1,500.00 per share and of Route Mobile IPO is ₹350.00 per share.

  Gland Pharma IPO Route Mobile IPO
Face Value ₹1 per share ₹10 per share
Issue Price (Lower) ₹1,490.00 per share ₹345.00 per share
Issue Price (Upper) ₹1,500.00 per share ₹350.00 per share
Issue Price (Final) ₹1,500.00 per share ₹350.00 per share
Discount (Retail)
Discount (Employee)
Market Lot Size 10 shares 40 shares
Fresh Issue Size 83,33,333 shares
Fresh Issue Size (Amount) up to ₹1,250.00 Cr up to ₹240.00 Cr
OFS Issue Size 3,48,63,635 shares
OFS Issue Size (Amount) up to ₹5,229.55 Cr up to ₹360.00 Cr
Issue Size Total 4,31,96,968 shares 1,73,91,303 shares
Issue Size Total (Amount) up to ₹6,479.55 Cr up to ₹600.00 Cr

IPO Timetable

Gland Pharma IPO opens on Nov 09, 2020, while Route Mobile IPO opens on Sep 09, 2020. The closing date of Gland Pharma IPO and Route Mobile IPO is Nov 11, 2020, and Sep 11, 2020, respectively.

  Gland Pharma IPO Route Mobile IPO
Anchor Bid Date
Issue Open Nov 09, 2020 Sep 09, 2020
Issue Close Nov 11, 2020 Sep 11, 2020
Basis Of Allotment (Tentative) Nov 17, 2020 Sep 16, 2020
Initiation of Refunds (Tentative) Nov 18, 2020 Sep 17, 2020
Credit of Share (Tentative) Nov 19, 2020 Sep 18, 2020
Listing date (Tentative) Nov 20, 2020 Sep 21, 2020
Anchor Lockin End date 1 Dec 17, 2020 Oct 16, 2020
Anchor Lockin End date 2 Feb 15, 2021 Dec 15, 2020

Financials

Gland Pharma IPO P/E ratio is , as compared to Route Mobile IPO P/E ratio of .

  Gland Pharma IPO Route Mobile IPO
Financial
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in million)
30-June-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 46,912.65 40,860.39 35,235.49 29,294.68
Total Revenue 9,162.89 27,724.08 21,297.67 16,716.82
Profit After Tax 3,135.90 7,728.58 4,518.56 3,210.51
Summary of financial Information (Restated Consolidated)
Particulars For the year/period ended (Rs in Million)
30-June-20 31-Mar-20 31-Mar-19 31-Mar-18
Total Assets 6,348.31 6,265.48 5,057.81 4,473.66
Total Revenue 3,122.95 9,681.02 8,523.77 5,094.85
Profit After Tax 269.34 691.02 545.32 466.77
Promoter Shareholding (Pre-Issue) 74% 96%
Promoter Shareholding (Post-Issue) 58% 66.33%
P/E Ratio
Market Cap
ROE
ROCE
Debt/Equity
EPS
RoNW

Shares Offered

In the Gland Pharma IPO retail investors (RII) are offered 1,51,18,939 shares while in Route Mobile IPO retail investors are offered 1,51,18,939 shares. Qualified institutional buyers (QIB) are offered 86,39,394 shares in Gland Pharma IPO and 34,78,259 shares in Route Mobile IPO.

  Gland Pharma IPO Route Mobile IPO
Anchor Investor Reserveration
Market Maker Reserveration
QIB 86,39,394 shares 34,78,259 shares
NII 64,79,546 shares 26,08,696 shares
RII 1,51,18,939 shares 60,86,957 shares
Employee 0 shares 0 shares
Others
Total 3,02,37,879 shares 1,21,73,912 shares

Bids Received (Subscription)

Gland Pharma IPO subscribed 2.06x in total, whereas Route Mobile IPO subscribed 73.30x.

  Gland Pharma IPO Route Mobile IPO
QIB (times) 6.40x 89.76x
NII (times) 0.51x 192.81x
Big NII (times)
Small NII (times)
RII (times) 0.24x 12.67x
Employee (times)
Other (times)
Total (times) 2.06x 73.30x

Comments

Add a public comment...